Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | MAP2K1 |
Variant | N109_R113del |
Impact List | deletion |
Protein Effect | gain of function |
Gene Variant Descriptions | MAP2K1 N109_R113del results in the deletion of five amino acids in the protein kinase domain of the Map2k1 protein from amino acids 109 to 113 (UniProt.org). N109_R113del confers a gain of function to the Map2k1 protein as indicated by increased Erk phosphorylation (PMID: 32641410, PMID: 30393068), and Mek phosphorylation in cultured cells (PMID: 30393068). |
Associated Drug Resistance | |
Category Variants Paths |
MAP2K1 mutant MAP2K1 act mut MAP2K1 N109_R113del |
Transcript | NM_002755.4 |
gDNA | chr15:g.66436779_66436793del15 |
cDNA | c.325_339del15 |
Protein | p.N109_R113delNQIIR |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_002755.4 | chr15:g.66436779_66436793del15 | c.325_339del15 | p.N109_R113delNQIIR | RefSeq | GRCh38/hg38 |
XM_011521783.4 | chr15:g.66436846_66436860del15 | c.326_340del15 | p.G109_S113delGAFYS | RefSeq | GRCh38/hg38 |
XM_017022411 | chr15:g.66436779_66436793del15 | c.325_339del15 | p.N109_R113delNQIIR | RefSeq | GRCh38/hg38 |
XM_017022412.1 | chr15:g.66436846_66436860del15 | c.326_340del15 | p.G109_S113delGAFYS | RefSeq | GRCh38/hg38 |
XM_017022413 | chr15:g.66485149_66485163del15 | c.325_339del15 | p.E109_R113delETPPR | RefSeq | GRCh38/hg38 |
XM_017022411.2 | chr15:g.66436779_66436793del15 | c.325_339del15 | p.N109_R113delNQIIR | RefSeq | GRCh38/hg38 |
NM_001411065.1 | chr15:g.66436846_66436860del15 | c.326_340del15 | p.G109_S113delGAFYS | RefSeq | GRCh38/hg38 |
NM_002755 | chr15:g.66436779_66436793del15 | c.325_339del15 | p.N109_R113delNQIIR | RefSeq | GRCh38/hg38 |
XM_017022411.3 | chr15:g.66436779_66436793del15 | c.325_339del15 | p.N109_R113delNQIIR | RefSeq | GRCh38/hg38 |
XM_017022412 | chr15:g.66436846_66436860del15 | c.326_340del15 | p.G109_S113delGAFYS | RefSeq | GRCh38/hg38 |
NM_002755.3 | chr15:g.66436779_66436793del15 | c.325_339del15 | p.N109_R113delNQIIR | RefSeq | GRCh38/hg38 |
XM_011521783 | chr15:g.66436846_66436860del15 | c.326_340del15 | p.G109_S113delGAFYS | RefSeq | GRCh38/hg38 |
XM_011521783.3 | chr15:g.66436846_66436860del15 | c.326_340del15 | p.G109_S113delGAFYS | RefSeq | GRCh38/hg38 |
XM_017022413.1 | chr15:g.66485149_66485163del15 | c.325_339del15 | p.E109_R113delETPPR | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MAP2K1 N109_R113del | Advanced Solid Tumor | predicted - sensitive | Trametinib | Preclinical - Biochemical | Actionable | In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation in transformed cells expressing MAP2K1 N109_R113del in culture (PMID: 32641410). | 32641410 |
MAP2K1 N109_R113del | Advanced Solid Tumor | predicted - sensitive | SCH772984 | Preclinical - Biochemical | Actionable | In a preclinical study, SCH772984 inhibited downstream signaling in transformed cells expressing MAP2K1 N109_R113del in culture (PMID: 32641410). | 32641410 |